PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17878251-8 2007 Nude mouse xenograft tumors derived from the BRAF mutant line ARO exhibited dose-dependent growth inhibition by AZD6244, with effective treatment at 10 mg/kg by oral gavage. AZD 6244 112-119 Braf transforming gene Mus musculus 45-49 24448821-7 2014 We found that the acquired MEK1-C121S mutation in BRAF-V600E mutant melanoma conferred resistance to both vemurafenib and selumetinib but not E6201. AZD 6244 122-133 Braf transforming gene Mus musculus 50-54 24132923-1 2013 PURPOSE: The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF(V600E) and is highly sensitive to the MEK inhibitor selumetinib (AZD6244). AZD 6244 142-153 Braf transforming gene Mus musculus 85-90 24132923-13 2013 These results suggest dual targeting BRAF (V600E) signaling and STAT3 signaling may be effective in selumetinib-resistant tumors or may retard or prevent onset of resistance. AZD 6244 100-111 Braf transforming gene Mus musculus 37-41